ReNeuron Group plc (LSE: RENE.L) today announces that it has entered into a further agreement with StemCells, Inc. (‘StemCells’), a leading US, NASDAQ-quoted adult stem cell development company. The agreement provides for ReNeuron to supply StemCells with cell lines generated using ReNeuron’s proprietary c-mycERTAM human stem cell immortalisation technology, for use in StemCells’ areas of therapeutic focus. These cell lines will be produced to standards appropriate for clinical and commercial use, such as GMP (Good Manufacturing Practice) and US GTP (Good Tissue Practice). ReNeuron will derive a commercial return from the supply of these cell lines to StemCells.
